Trial NCT04139317

View at ClinicalTrials.gov 
Org. Study IDs: CINC280I12201
Secondary IDs: 2019-002660-27

Last trial update was posted on 2024-02-08

MeSH Interventions

Pembrolizumab

MeSH Conditions

Carcinoma, Non-Small-Cell Lung Lung Neoplasms

Other Conditions

Non-small Cell Lung Cancer (NSCLC)

Stopping Reasons

Sponsor decision to terminate due to the lack of tolerability observed in patients treated with capmatinib and pembrolizumab in the combination arm as compared to patients treated with pembrolizumab alone in the pembrolizumab single agent arm

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID